XBiotech (NASDAQ:XBIT) is a biopharmaceutical company engaged in discovering, developing, and commercializing novel antibodies for various diseases. The company's diverse pipeline focuses on addressing unmet medical needs in multiple therapeutic areas, emphasizing oncology, infectious diseases, and inflammatory conditions. XBiotech employs a proprietary technology platform to create unique therapeutic antibodies that aim to improve patient outcomes. Their mission revolves around harnessing the power of natural immunity to transform treatment paradigms and enhance the quality of life for patients globally. By concentrating on innovation and leveraging its research and development expertise, XBiotech strives to advance its projects from discovery through clinical development, aiming to bring groundbreaking treatments to the market.